Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Cipla, Pfizer and DRL...

    Cipla, Pfizer and DRL among 66 drug firms that fail quality test

    Written by Ruby Khatun Khatun Published On 2017-07-23T09:52:28+05:30  |  Updated On 23 July 2017 9:52 AM IST
    Cipla, Pfizer and DRL among  66 drug firms that fail quality test

    Some of Major drug companies like Pfizer, Alembic Pharma, Cipla, Dr Reddy’s Laboratories & Zydus Healthcare are among 66 drug companies that have failed the test for Not of Standard Quality (NSQ) drugs, according to a report released by CDSCO.


    In a bid to bring down the proportion of its substandard drugs to 2% over the next three years to match global standards, National Institute of Biologicals was deputed by Ministry of Health and Family Welfare to conduct the National Drug Survey across the country. The institute was asked to check and ascertain the proportion of drug samples failing in Quality testing and tabulate them.


    The survey, conducted to check the proportion of substandard drugs in the country, had tested 47,012 samples from 1,719 manufacturing units, CDSCO said. Around 3.16% of these samples were found to be not of standard quality. The estimated percentage of NSQ drugs from government sources was 10.02% and the percentage of spurious drugs was 0.05%. Globally, the acceptable rate is around 2%.


    Joint Secretary (Regulation), Ministry of Health & Family Welfare in general review meeting about CDSCO, held on 06.07.2017 decided that the list of drug manufacturers where more than five samples have been failed, be put on CDSCO Website separately.


    Accordingly the report was displayed which states that Pfizer has failed the test for 25 samples, Dr Reddy’s Laboratories and Alembic have 9 NSQ samples each. In addition to this seven samples of Cipla, and six samples of Zydus Healthcare have failed the government’s test.


    Find the attachment for the same.


    http://www.cdsco.nic.in/writereaddata/National%20Drug%20Survey.pdf

    Alembic PharmaCDSCOCiplacountryDr Reddy's Laboratoriesdrug samplesfailfailingMinistry of Health and Family WelfareNational Drug SurveyNational Institute of BiologicalsPfizerQuality testingZydus Healthcare

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok